{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T15:57:56Z","timestamp":1773849476072,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.ijrobp.2022.06.080","type":"journal-article","created":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T13:06:03Z","timestamp":1661605563000},"page":"693-704","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Extended Results and Independent Validation of a Phase 2 Trial of Metastasis-Directed Therapy for Molecularly Defined Oligometastatic Prostate Cancer"],"prefix":"10.1016","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0555-8754","authenticated-orcid":false,"given":"Rachel M.","family":"Glicksman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Ramotar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ur","family":"Metser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter W.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglass","family":"Vines","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Finelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil E.","family":"Fleshner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Perlis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre R.","family":"Zlotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Bayley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joelle","family":"Helou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srinivas","family":"Raman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Girish","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Catton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosanna","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Padraig","family":"Warde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Gospodarowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Jaffray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Berlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2022.06.080_bib0001","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: A prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.080_bib0002","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: The oriole phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.080_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2021.02.031","article-title":"Curative-intent metastasis-directed therapies for molecularly-defined oligorecurrent prostate cancer: A prospective phase ii trial testing the oligometastasis hypothesis","author":"Glicksman","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2022.06.080_bib0004","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-035959","article-title":"[(18)f]dcfpyl pet-mri\/ct for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: Study protocol for a phase ii trial","volume":"10","author":"Glicksman","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.ijrobp.2022.06.080_bib0005","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1016\/j.prro.2016.05.004","article-title":"Rationale of technical requirements for NRG-BR001: The first NCI-sponsored trial of sbrt for the treatment of multiple metastases","volume":"6","author":"Al-Hallaq","year":"2016","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.080_bib0006","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1001\/jamaoncol.2021.0687","article-title":"Evaluation of safety of stereotactic body radiotherapy for the treatment of patients with multiple metastases: Findings from the NRG-BR001 phase 1 trial","volume":"7","author":"Chmura","year":"2021","journal-title":"JAMA Oncology"},{"key":"10.1016\/j.ijrobp.2022.06.080_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ijrobp.2022.06.080_bib0008","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.eururo.2018.06.004","article-title":"Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: A prospective clinical trial","volume":"74","author":"Siva","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2022.06.080_bib0009","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): A randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2022.06.080_bib0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13014-016-0586-x","article-title":"[18f]choline PET\/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: Preliminary results","volume":"11","author":"Pasqualetti","year":"2016","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.080_bib0011","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.euo.2018.04.017","article-title":"Stereotactic body radiotherapy for oligometastatic prostate cancer detected via prostate-specific membrane antigen positron emission tomography","volume":"1","author":"Kneebone","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.080_bib0012","doi-asserted-by":"crossref","first-page":"E250","DOI":"10.1016\/j.ijrobp.2016.06.1250","article-title":"Outcomes after a first and\/or second salvage treatment in patients with oligometastatic prostate cancer recurrence detected by (18-f) choline positron emission tomography\/computed tomography","volume":"96","author":"Gomez-Iturriaga","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.06.080_bib0013","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.juro.2015.04.103","article-title":"Management of node only recurrence after primary local treatment for prostate cancer: A systematic review of the literature","volume":"194","author":"Ploussard","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2022.06.080_bib0014","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.eururo.2014.02.011","article-title":"Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: Results of a single-institution series with a minimum follow-up of 5 years","volume":"67","author":"Suardi","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2022.06.080_bib0015","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.eururo.2020.06.043","article-title":"Long-term outcomes of salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy: Not as good as previously thought","volume":"78","author":"Bravi","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2022.06.080_bib0016","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1001\/jamaoncol.2021.3771","article-title":"Diagnostic accuracy of 68GA-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: A multicenter prospective phase 3 imaging trial","volume":"7","author":"Hope","year":"2021","journal-title":"JAMA Oncology"},{"key":"10.1016\/j.ijrobp.2022.06.080_bib0017","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1186\/s12885-020-06911-4","article-title":"Peace V - salvage treatment of oligorecurrent nodal prostate cancer metastases (STORM): A study protocol for a randomized controlled phase II trial","volume":"20","author":"De Bruycker","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2022.06.080_bib0018","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41391-021-00432-2","article-title":"Radiation therapy dose and androgen deprivation therapy in localized prostate cancer: A meta-regression of 5-year outcomes in phase III randomized controlled trials","volume":"25","author":"Jiang","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ijrobp.2022.06.080_bib0019","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1200\/JCO.21.00376","article-title":"End point definitions and surrogacy in prostate cancer: Will metastasis-free survival become event-free survival with advances in molecular imaging?","volume":"39","author":"Dess","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.080_bib0020","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1470-2045(16)00107-8","article-title":"Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): A randomised, multicentre, non-blinded, phase 3 trial","volume":"17","author":"Duchesne","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.080_bib0021","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1200\/JCO.20.03256","article-title":"Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update","volume":"39","author":"Virgo","year":"2021","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.ijrobp.2022.06.080_bib0022","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/S0022-510X(09)71300-0","article-title":"The will rogers phenomenon: The effect of different diagnostic criteria","volume":"287","author":"Sormani","year":"2009","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.ijrobp.2022.06.080_bib0023","doi-asserted-by":"crossref","unstructured":"Glicksman RM, Berlin A. Reply to Wei Liu, Katherine Zukotynski, and Glenn Bauman's Letter to the Editor re: Rachel M. Glicksman, Ur Metser, Douglass Vines, et al. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. Eur Urol 2021;80(3):E79-E80.","DOI":"10.1016\/j.eururo.2021.06.004"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301622006447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301622006447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T10:01:18Z","timestamp":1759744878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301622006447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0360301622006447"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2022.06.080","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extended Results and Independent Validation of a Phase 2 Trial of Metastasis-Directed Therapy for Molecularly Defined Oligometastatic Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2022.06.080","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}